Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia-Reference-Cited by-同舟云学术

Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia

Published:2019-08-05 Issue:1 Volume:61 Page:225-227
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ong Shin Yeu¹^ORCID,Phipps Colin²,Nagarajan Chandramouli¹,Tang Tiffany³,Lim Soon Thye³,Goh Yeow Tee¹,Lee Yuh Shan²

Affiliation:

1. Department of Haematology, Singapore General Hospital, Singapore;

2. Parkway Cancer Centre, Singapore;

3. National Cancer Center, Singapore

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1648805

Reference14 articles.

1. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

2. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

3. The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis

4. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era

5. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma;Journal of Clinical Oncology;2023-12-10

2. Model for Predicting Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Discussion of Prophylaxis Measures;World Neurosurgery;2023-11

3. Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?;Blood Reviews;2023-09

4. Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse;Hematological Oncology;2023-06-29

5. Circulating Tumor DNA in Lymphoma;Molecular Pathology Library;2023